Loading…
Lobbying Spend
—
Filings
687
Firms Hired
19
Active Period
1999–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Transparent PRICE Act
2023 · second_quarter · Firm: TARPLIN, DOWNS & YOUNG, LLC
S.1339 the Pharmacy Benefit Manager Reform Act H.R.3281 Transparent P.R.I.C.E Act H.R.581 Help Ensure Lower Patient Copays Act IRA implementation, innovation, 340B, pandemic preparedness, orphan drugs, PAPHA reauthorization
Client expense: — · Firm income: $80,000
Matched citations: H.R.3281
S.1339 the Pharmacy Benefit Manager Reform Act H.R.3281 Transparent P.R.I.C.E Act H.R.581 Help Ensure Lower Patient Copays Act IRA implementation, innovation, 340B, pandemic preparedness, orphan drugs, PAPHA reauthorization
Client expense: — · Firm income: $80,000
Matched citations: H.R.581
Pharmacy Benefit Manager Reform Act
2023 · second_quarter · Firm: TARPLIN, DOWNS & YOUNG, LLC
S.1339 the Pharmacy Benefit Manager Reform Act H.R.3281 Transparent P.R.I.C.E Act H.R.581 Help Ensure Lower Patient Copays Act IRA implementation, innovation, 340B, pandemic preparedness, orphan drugs, PAPHA reauthorization
Client expense: — · Firm income: $80,000
Matched citations: S.1339
Consolidated Appropriations Act, 2023
2022 · fourth_quarter · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 5376, the Inflation Reduction Act H.R.2617, Consolidated Appropriations Act, 2023 Biosimilars, FDA policies, innovation, 340B, comparative effectiveness research, non-interference, opioids, pandemic preparedness, user fee reauthorization
Client expense: — · Firm income: $80,000
Matched citations: H.R.2617
Consolidated Appropriations Act, 2023
2022 · fourth_quarter · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R.2617 - Consolidated Appropriations Act, 2023
Client expense: — · Firm income: $80,000
Matched citations: H.R.2617
Inflation Reduction Act of 2022
2022 · fourth_quarter · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 5376, the Inflation Reduction Act H.R.2617, Consolidated Appropriations Act, 2023 Biosimilars, FDA policies, innovation, 340B, comparative effectiveness research, non-interference, opioids, pandemic preparedness, user fee reauthorization
Client expense: — · Firm income: $80,000
Matched citations: H.R. 5376
Inflation Reduction Act of 2022
2022 · fourth_quarter · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 5376, the Inflation Reduction Act
Client expense: — · Firm income: $80,000
Matched citations: H.R. 5376
Food and Drug Amendments of 2022
2022 · fourth_quarter · Firm: TARPLIN, DOWNS & YOUNG, LLC
S. 4348, FDA Safety and Landmark Advancements Act H.R. 7667, Food and Drug Amendments of 2022 drug safety, prescription drug importation, import safety, supply chain integrity, biosimilars, PDUFA and associated policies, patent settlements, accelerated approval, break through therapies, compounding, user fee reauthorization, innovation, transparency
Client expense: — · Firm income: $80,000
Matched citations: H.R. 7667
S. 4348, FDA Safety and Landmark Advancements Act H.R. 7667, Food and Drug Amendments of 2022 drug safety, prescription drug importation, import safety, supply chain integrity, biosimilars, PDUFA and associated policies, patent settlements, accelerated approval, break through therapies, compounding, user fee reauthorization, innovation, transparency
Client expense: — · Firm income: $80,000
Matched citations: S. 4348
Consolidated Appropriations Act, 2023
2022 · fourth_quarter · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R.2617 - Consolidated Appropriations Act, 2023
Client expense: — · Firm income: $80,000
Matched citations: H.R.2617
Consolidated Appropriations Act, 2023
2022 · fourth_quarter · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 5376, the Inflation Reduction Act H.R.2617, Consolidated Appropriations Act, 2023 Biosimilars, FDA policies, innovation, 340B, comparative effectiveness research, non-interference, opioids, pandemic preparedness, user fee reauthorization
Client expense: — · Firm income: $80,000
Matched citations: H.R.2617
Inflation Reduction Act of 2022
2022 · fourth_quarter · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 5376, the Inflation Reduction Act H.R.2617, Consolidated Appropriations Act, 2023 Biosimilars, FDA policies, innovation, 340B, comparative effectiveness research, non-interference, opioids, pandemic preparedness, user fee reauthorization
Client expense: — · Firm income: $80,000
Matched citations: H.R. 5376
Inflation Reduction Act of 2022
2022 · fourth_quarter · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 5376, the Inflation Reduction Act
Client expense: — · Firm income: $80,000
Matched citations: H.R. 5376
Food and Drug Amendments of 2022
2022 · fourth_quarter · Firm: TARPLIN, DOWNS & YOUNG, LLC
S. 4348, FDA Safety and Landmark Advancements Act H.R. 7667, Food and Drug Amendments of 2022 drug safety, prescription drug importation, import safety, supply chain integrity, biosimilars, PDUFA and associated policies, patent settlements, accelerated approval, break through therapies, compounding, user fee reauthorization, innovation, transparency
Client expense: — · Firm income: $80,000
Matched citations: H.R. 7667
S. 4348, FDA Safety and Landmark Advancements Act H.R. 7667, Food and Drug Amendments of 2022 drug safety, prescription drug importation, import safety, supply chain integrity, biosimilars, PDUFA and associated policies, patent settlements, accelerated approval, break through therapies, compounding, user fee reauthorization, innovation, transparency
Client expense: — · Firm income: $80,000
Matched citations: S. 4348
Elijah E. Cummings Lower Drug Costs Now Act
2022 · third_quarter · Firm: PUBLIC STRATEGIES WASHINGTON, INC.
Issues relating to prescription drug pricing, oversight, patents, and intellectual property in Medicare and generally, including proposed reform proposals (H.R. 3) Issues relating to biologics and biosimilars in Medicare and generally.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 3
Inflation Reduction Act of 2022
2022 · third_quarter · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 5376, the Inflation Reduction Act Biosimilars, FDA policies, innovation, 340B, comparative effectiveness research, non-interference, opioids, pandemic preparedness, user fee reauthorization
Client expense: — · Firm income: $80,000
Matched citations: H.R. 5376
Inflation Reduction Act of 2022
2022 · third_quarter · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 5376, the Inflation Reduction Act
Client expense: — · Firm income: $80,000
Matched citations: H.R. 5376
Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
2022 · third_quarter · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 6833, Continuing Appropriations and Ukraine Supplemental Appropriations Act of 2023
Client expense: — · Firm income: $80,000
Matched citations: H.R. 6833
Food and Drug Amendments of 2022
2022 · third_quarter · Firm: TARPLIN, DOWNS & YOUNG, LLC
S. 4348, FDA Safety and Landmark Advancements Act H.R. 7667, Food and Drug Amendments of 2022 drug safety, prescription drug importation, import safety, supply chain integrity, biosimilars, PDUFA and associated policies, patent settlements, accelerated approval, break through therapies, compounding, user fee reauthorization, innovation, transparency
Client expense: — · Firm income: $80,000
Matched citations: H.R. 7667
S. 4348, FDA Safety and Landmark Advancements Act H.R. 7667, Food and Drug Amendments of 2022 drug safety, prescription drug importation, import safety, supply chain integrity, biosimilars, PDUFA and associated policies, patent settlements, accelerated approval, break through therapies, compounding, user fee reauthorization, innovation, transparency
Client expense: — · Firm income: $80,000
Matched citations: S. 4348
Elijah E. Cummings Lower Drug Costs Now Act
2022 · second_quarter · Firm: PUBLIC STRATEGIES WASHINGTON, INC.
Issues relating to prescription drug pricing, oversight, patents, and intellectual property in Medicare and generally, including proposed reform proposals (H.R. 3) Issues relating to biologics and biosimilars in Medicare and generally.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 3
Consolidated Appropriations Act, 2022
2022 · second_quarter · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 2471, Consolidated Appropriations Act 2022 deficit reduction, appropriations, ARPA-H, reconciliation
Client expense: — · Firm income: $80,000
Matched citations: H.R. 2471
Inflation Reduction Act of 2022
2022 · second_quarter · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 5376, the Build Back Better Act
Client expense: — · Firm income: $80,000
Matched citations: H.R. 5376
Inflation Reduction Act of 2022
2022 · second_quarter · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 5376, the Build Back Better Act Biosimilars, FDA policies, innovation, 340B, comparative effectiveness research, non-interference, opioids, pandemic preparedness, user fee reauthorization
Client expense: — · Firm income: $80,000
Matched citations: H.R. 5376
Source: Senate LDA